PROTAC ERα Degrader-4

Name: PROTAC ERα Degrader-4
Brand: MedChemExpress
SKU: HY-149295
Rating: 4.5 (1 reviews)

Cat. No.: HY-149295 Purity: 98.63%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

PROTAC ERα Degrader-4 is a highly potent and selectivePROTAC ERα degrader (K_i: 5.08 μM). PROTAC ERα Degrader-4 contains OBHSAs, linker and E3 ligase ligands. PROTAC ERα Degrader-4 shows excellent cell inhibitory and ERα degradation activity against Tamoxifen-sensitive and -resistant ER⁺ breast cancer (BC) cells and ERα-mutated BC cells. PROTAC ERα Degrader-4 can induce apoptosis and can be used for cancer research.

For research use only. We do not sell to patients.

PROTAC ERα Degrader-4 Chemical Structure

CAS No. : 2521299-80-7

Size	Stock	Quantity
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All PROTACs Isoform Specific Products:

View All Isoforms

von Hippel-Lindau (VHL) Cereblon MDM2 cIAP1

View All Estrogen Receptor/ERR Isoform Specific Products:

View All Isoforms

Estrogen receptor ERα ERβ ERRα ERRβ ERRγ

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

ERα

5.08 μM (Ki)

ERβ

26.20 μM (Ki)

In Vitro

PROTAC ERα Degrader-4 (1 μM, 12 hours) exhibits significant degradation activity for ERα in MCF-7cells^[1].
PROTAC ERα Degrader-4 (2 μM, 12 hours) can degrade wild-type ERα inT47D cells and mutant ERα in T47D^D538G and T47D^Y537S cells^[1].
PROTAC ERα Degrader-4 (0.01-10 μM, 72 hours) has inhibitory activity of ERα in Tamoxifen (HY-13757A) -sensitive MCF-7 cells, with the IC₅₀ value of 0.05 μM^[1].
PROTAC ERα Degrader-4 (1-10 μM, 72 hours) induce apoptosis and cell cycle arrest of MCF-7 cells^[1].
PROTAC ERα Degrader-4 (0.01-10 μM, 12 hours) efficiently degrades ERα protein in the range of 0.01 to10 μM in MCF-7 cell line^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	MCF-7 cells
Concentration:	0.01-10 μM
Incubation Time:	72 hours
Result:	Had inhibitory activity in Tamoxifen-sensitive MCF-7 cells, with the IC₅₀ value of 0.05 μM.

Apoptosis Analysis^[1]

Cell Line:	MCF-7 cells
Concentration:	1.0 μM, 5 μM, 5.0 μM
Incubation Time:	72 hours
Result:	Induced apoptosis.

Cell Cycle Analysis^[1]

Cell Line:	MCF-7 cells
Concentration:	0.01-10 μM
Incubation Time:	72 hours
Result:	Induced cell cycle arrest.

Western Blot Analysis^[1]

Cell Line:	MCF-7 cells
Concentration:	0.01-10 μM
Incubation Time:	12 hours
Result:	Efficiently degraded ERα protein in the range of 0.01 to10 μM, whereas ERα protein levels recovered slightly at a high concentration of 10 μM

In Vivo

PROTAC ERα Degrader-4 (Compound ZD12) (5 μM/kg for i.p., once every 2 days) exhibits potent antitumor activity and ERα degradation effect in tumor tissues in LCC2 orthotopic xenograft tumor models^[1].
PROTAC ERα Degrader-4 (5 mg/kg for i.v.) shows a T_1/2 of 4.61 h and CL of 64.4 mL/min/kg^[1].

Pharmacokinetic parameters for PROTAC ERα Degrader-4 (Compound ZD12) in BALB/C female mice^[1]

ND: not detected.

Route	Dose (mg/kg)	CL (mL/min/kg)	T_max (h)	T_1/2 (h)	C_max (ng/mL)	AUC (h•ng/mL)
i.v.	5	64.4	0.08	4.61	3635.73	1342
p.o.	20	ND	ND	ND	ND	ND

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	LCC2 orthotopic xenograft tumor models^[1]
Dosage:	5 μM/kg
Administration:	Intravenous injection (i.p.)
Result:	Exhibited potent antitumor activity and ERα degradation effect in tumor tissues.

Animal Model:	BALB/C female mice (Pharmacokinetic assay)^[1]
Dosage:	5 mg/kg; 20 mg/kg
Administration:	Intravenous injection (i.v.); Oral gavage (p.o.)
Result:

Molecular Weight

1074.23

Formula

C₅₅H₆₂F₃N₅O₁₀S₂

CAS No.

2521299-80-7

Appearance

Solid

Color

White to light yellow

SMILES

CC1=C(C2=CC=C(C=C2)[C@@H](NC([C@@H]3C[C@H](CN3C([C@@H](NC(CCCCCOC4=CC=C(C=C4)N(CC(F)(F)F)S(C5C[C@@H]6C(C7=CC=C(C=C7)O)=C([C@H]5O6)C8=CC=C(C=C8)O)(=O)=O)=O)C(C)(C)C)=O)O)=O)C)SC=N1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (93.09 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.9309 mL	4.6545 mL	9.3090 mL
5 mM	0.1862 mL	0.9309 mL	1.8618 mL
10 mM	0.0931 mL	0.4654 mL	0.9309 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: 98.63%

Select Batch:

Data Sheet (281 KB) SDS (252 KB)

COA (253 KB) HNMR (322 KB) RP-HPLC (291 KB) LCMS (138 KB)

Handling Instructions (2659 KB)

References

[1]. Xie B, et.al. Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer In Vitro and In Vivo. J Med Chem. 2023 May 25;66(10):6631-6651. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	0.9309 mL	4.6545 mL	9.3090 mL	23.2725 mL
	5 mM	0.1862 mL	0.9309 mL	1.8618 mL	4.6545 mL
	10 mM	0.0931 mL	0.4654 mL	0.9309 mL	2.3272 mL
	15 mM	0.0621 mL	0.3103 mL	0.6206 mL	1.5515 mL
	20 mM	0.0465 mL	0.2327 mL	0.4654 mL	1.1636 mL
	25 mM	0.0372 mL	0.1862 mL	0.3724 mL	0.9309 mL
	30 mM	0.0310 mL	0.1551 mL	0.3103 mL	0.7757 mL
	40 mM	0.0233 mL	0.1164 mL	0.2327 mL	0.5818 mL
	50 mM	0.0186 mL	0.0931 mL	0.1862 mL	0.4654 mL
	60 mM	0.0155 mL	0.0776 mL	0.1551 mL	0.3879 mL
	80 mM	0.0116 mL	0.0582 mL	0.1164 mL	0.2909 mL